phenylhexyl isocyanate | 143819-12-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: phenylhexyl isocyanate
• 英文别名: (6-isocyanatohexyl)benzene；6-phenyl-1-hexyl isocyanate；6-phenylhexan-1-yl-isocyanate；6-isocyanatohexylbenzene
• CAS: 143819-12-9
• 化学式: C₁₃H₁₇NO
• 分子量: 203.284
• InChiKey: VHPUQFPLELPBHO-UHFFFAOYSA-N

物化性质

• 沸点：
  311.1±21.0 °C(Predicted)
• 密度：
  0.94±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  29.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  phenylhexyl isocyanate 在 4-二甲氨基吡啶 、 苯甲醚 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 4-<(4-carboxyphenyl)oxy>-3,3-diethyl-1-<<(6-phenylhexyl)amino>carbonyl>-2-azetidinone
  参考文献：
  名称：

  Orally active .beta.-lactam inhibitors of human leukocyte elastase-1. Activity of 3,3-diethyl-2-azetidinones

  摘要：

  A thorough analysis of the mechanism of inhibition of human leukocyte elastase (HLE) by a monocyclic beta-lactam and the mechanism of beta-lactam hydrolysis led to the preparation of potent and highly stable inhibitors of HLE. This work led to the identification of 4-[(4-carboxyphenyl)-oxy]-3,3-diethyl-1-[[(phenylmethyl)amino]carbonyl]-2-azetidinone (2) as the first orally active inhibitor of human leukocyte elastase (HLE). Analogs of 2 with different substituents on the urea N were synthesized and evaluated for their activity in vitro against HLE as well as in vivo in a hamster lung hemorrhage model. Compounds with a methyl or a methoxy group in the para position of the benzene ring were very potent in both assays. The results are discussed on the basis of the proposed model for the binding of this class of inhibitors to HLE and a possible mechanism of inhibition is presented.

  DOI：

  10.1021/jm00099a003
• 作为产物：
  描述：

  7-苯基庚酸 在 sodium azide 、 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 、 氯仿 、 水 、 丙酮 为溶剂， 反应 1.42h， 生成 phenylhexyl isocyanate
  参考文献：
  名称：

  Orally active .beta.-lactam inhibitors of human leukocyte elastase-1. Activity of 3,3-diethyl-2-azetidinones

  摘要：

  A thorough analysis of the mechanism of inhibition of human leukocyte elastase (HLE) by a monocyclic beta-lactam and the mechanism of beta-lactam hydrolysis led to the preparation of potent and highly stable inhibitors of HLE. This work led to the identification of 4-[(4-carboxyphenyl)-oxy]-3,3-diethyl-1-[[(phenylmethyl)amino]carbonyl]-2-azetidinone (2) as the first orally active inhibitor of human leukocyte elastase (HLE). Analogs of 2 with different substituents on the urea N were synthesized and evaluated for their activity in vitro against HLE as well as in vivo in a hamster lung hemorrhage model. Compounds with a methyl or a methoxy group in the para position of the benzene ring were very potent in both assays. The results are discussed on the basis of the proposed model for the binding of this class of inhibitors to HLE and a possible mechanism of inhibition is presented.

  DOI：

  10.1021/jm00099a003

文献信息

• [EN] CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS<br/>[FR] DÉRIVÉS CARBAMATES EN PARTICULIER POUR LE TRAITEMENT DE TROUBLES NEUROLOGIQUES
  申请人：SIGMA TAU IND FARMACEUTI

  公开号：WO2010105930A1

  公开（公告）日：2010-09-23

  The present invention relates to new carbamate derivatives of formula I, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of neurological disorders, such as neuropathic pain and anxiety.

  本发明涉及一类新的氨基甲酸衍生物，其化学式为I，包括它们的制备方法，以及包含这些化合物的药物组合物，用于治疗神经系统疾病，如神经性疼痛和焦虑。
• Design and synthesis of uracil urea derivatives as potent and selective fatty acid amide hydrolase inhibitors
  作者：Yan Qiu、Jie Ren、Hongwei Ke、Yang Zhang、Qi Gao、Longhe Yang、Canzhong Lu、Yuhang Li

  DOI：10.1039/c7ra02237a

  日期：——

  picomolar FAAH inhibitors (4c, IC50 = 0.3 ± 0.05 nM; 4d, IC50 = 0.8 ± 0.1 nM) were developed. Compound 4c inhibited FAAH in a rapid, selective, noncompetitive, and irreversible pattern. This study provides several highly potent and selective FAAH inhibitors and an optimized chemical scaffold for the development of FAAH inhibitors. We anticipate that these FAAH inhibitors will enable new possibilities in

  脂肪酸酰胺水解酶（FAAH）是参与内源性大麻素（尤其是anandamide）生物降解的关键酶之一。FAAH的药理学阻断作用可恢复内源性大麻素的水平，从而在治疗炎症，抑郁和多发性硬化症方面提供治疗益处。在这项研究中，设计并合成了一系列尿嘧啶脲衍生物作为FAAH抑制剂。N-己基-2,4-二氧代-3,4-二氢嘧啶-1（2 H）-羧酰胺（1a的C5位置和侧链的结构修饰）导致FAAH抑制剂具有更高的效能和选择性。结构-活性关系（SAR）研究表明，C5吸电子取代基优选具有最佳效能，但不具有选择性，而用苯基烷基基团或联苯基取代烷基链可显着提高抑制效力和对FAAH的选择性。开发了两种高效的皮摩尔FAAH抑制剂（4c，IC 50 = 0.3±0.05 nM; 4d，IC 50 = 0.8±0.1 nM）。化合物4c以快速，选择性，非竞争性和不可逆的方式抑制FAAH。这项研究提供了几种高效和选择性的FAAH抑
• Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer’s Disease Agents
  作者：Serena Montanari、Laura Scalvini、Manuela Bartolini、Federica Belluti、Silvia Gobbi、Vincenza Andrisano、Alessia Ligresti、Vincenzo Di Marzo、Silvia Rivara、Marco Mor、Alessandra Bisi、Angela Rampa

  DOI：10.1021/acs.jmedchem.6b00609

  日期：2016.7.14

  a viable avenue for the treatment of neurodegeneration, being involved in neuroprotective and anti-inflammatory processes. In particular, indirectly enhancing endocannabinoid signaling to therapeutic levels through FAAH inhibition might be beneficial for neurodegenerative disorders such as Alzheimer’s disease, effectively preventing or slowing the progression of the disease. Hence, in the search for

  内源性大麻素系统的调节正在成为治疗神经退行性疾病的可行途径，参与神经保护和抗炎过程。特别地，通过FAAH抑制间接增强内源性大麻素信号传导至治疗水平可能有益于神经退行性疾病，例如阿尔茨海默氏病，有效预防或减慢疾病的发展。因此，在寻找更有效的阿尔茨海默氏病治疗方法中，本文将多目标导向的配体范式用于氨基甲酸酯的设计，该氨基甲酸酯能够同时靶向最近提出的内源性大麻素系统和经典的胆碱酯酶系统，并实现有效的双重治疗。 FAAH /胆碱酯酶抑制剂。在这两个合成的化合物系列中，9和19被确定为有效的双重FAAH / ChE抑制剂，具有均衡的纳摩尔活性。因此，9和19可被视为阿尔茨海默氏病治疗的新有希望的候选者。
• Selective Fatty Acid Amide Hydrolase Inhibitors as Potential Novel Antiepileptic Agents
  作者：Alessandro Grillo、Filomena Fezza、Giulia Chemi、Roberto Colangeli、Simone Brogi、Domenico Fazio、Stefano Federico、Alessandro Papa、Nicola Relitti、Roberto Di Maio、Gianluca Giorgi、Stefania Lamponi、Massimo Valoti、Beatrice Gorelli、Simona Saponara、Mascia Benedusi、Alessandra Pecorelli、Patrizia Minetti、Giuseppe Valacchi、Stefania Butini、Giuseppe Campiani、Sandra Gemma、Mauro Maccarrone、Giuseppe Di Giovanni

  DOI：10.1021/acschemneuro.1c00192

  日期：2021.5.5

  antiepileptic effects, devoid of psychotropic effects. We herein report the discovery of selective anandamide catabolic enzyme fatty acid amide hydrolase (FAAH) inhibitors with promising antiepileptic efficacy, starting from a further investigation of our prototypical inhibitor 2a. When tested in two rodent models of epilepsy, 2a reduced the severity of the pilocarpine-induced status epilepticus and the elongation

  颞叶癫痫是癫痫的最常见形式，目前的抗癫痫药对许多患者无效。内源性大麻素系统与癫痫发作的按需保护反应有关。阻断内源性大麻素分解代谢将引起抗癫痫作用，而没有精神作用。我们从对我们的原型抑制剂2a的进一步研究开始，报告了发现具有前途抗癫痫功效的选择性anandamide分解代谢酶脂肪酸酰胺水解酶（FAAH）抑制剂的发现。在两个啮齿动物癫痫模型中进行测试时，2a降低了毛果芸香碱引起的癫痫持续状态的严重性以及海马最大齿状激活的延长。值得注意的是，2a没有影响海马齿状回的长期突触可塑性。这些数据促使我们进一步努力，旨在发现新的抗癫痫药，开发出一套新的FAAH抑制剂（3a – m）。生物学研究强调3h和3m是表现最好的类似物，有待进一步研究。在基于细胞的研究中，使用成神经细胞瘤细胞系3h和3m可以通过降低NF-kB p65的DNA结合活性来减少恶性炎症状态，而没有细胞毒性作用。在3小时内排除了有害的心脏
• Development of Potent Inhibitors of Fatty Acid Amide Hydrolase Useful for the Treatment of Neuropathic Pain
  作者：Margherita Brindisi、Giuseppe Borrelli、Simone Brogi、Alessandro Grillo、Samuele Maramai、Marco Paolino、Mascia Benedusi、Alessandra Pecorelli、Giuseppe Valacchi、Lorenzo Di Cesare Mannelli、Carla Ghelardini、Marco Allarà、Alessia Ligresti、Patrizia Minetti、Giuseppe Campiani、Vincenzo di Marzo、Stefania Butini、Sandra Gemma

  DOI：10.1002/cmdc.201800397

  日期：2018.10.8

  6‐oxo‐5,6‐dihydro‐4H‐benzo[f]pyrrolo[1,2‐a][1,4]diazepin‐9‐yl‐6‐phenylhexylcarbamate (5 h) and 4‐oxo‐5,6‐dihydro‐4H‐benzo[f]pyrrolo[1,2‐a][1,4]diazepin‐9‐yl‐(6‐phenylhexyl)carbamate (5 i) (nanomolar FAAH inhibitors, the latter of which also shows micromolar affinity at the CB1R), were selected for further studies. Results of cell‐based studies on a neuroblastoma cell line (IMR32) demonstrated 5 h, 5 i, and

  脂肪酸酰胺水解酶（FAAH）在终止内源性大麻素（EC）信号传导中的独特作用支持了其作为治疗靶标的相关性。EC代谢酶的抑制引起大麻素受体（CBR）的间接激动作用，并且缺乏精神治疗作用。基于我们以前的配体，并针对发现新的选择性FAAH抑制剂，我们开发了一系列以功能化三环骨架为特征的12种新化合物。所有已开发的化合物对单酰基甘油脂肪酶（MAGL）和CBR的活性均可以忽略不计。新开发的系列中最有效的FAAH抑制剂6-氧代-5,6-二氢-4 H-苯并[ f ]吡咯并[1,2- a ] [1,4]二氮杂pin-9-基-6-苯基己基氨基甲酸酯（5小时）和4-氧代-5,6-二氢-4 H-苯并[ f ]吡咯并[1,2- a ] [1,4]二氮杂pin-9-基-（6-苯基己基）氨基甲酸酯（5 i）（纳摩尔选择FAAH抑制剂（后者在CB 1 R处也显示微摩尔亲和力）进行进一步研究。对神经母细胞瘤细胞系（IMR32）进行的基于细胞的研究结果表明，5